Biocon Biologics announces positive results from Phase 3 Study of Yesintek biosimilar to Ustekinumab… EP News Bureau Mar 8, 2025 The safety profile of YESINTEK was similar to the reference product Stelara (Ustekinumab) throughout the duration of the study
DRL in agreement with XenoPort Usha Sharma Mar 28, 2016 DRL will be granted exclusive US rights for the development and commercialisation of XenoPort’s clinical-stage oral new chemical…
